Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

NCT ID: NCT05237245

Last Updated: 2025-11-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-23

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoproliferation Induced by HTLV-1 HTLV-1 Adult T-cell Lymphoma / Leukemia HTLV-1 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Adult T-cell leukemia / lymphoma (ATL) patients

No interventions assigned to this group

2

HTLV-1 chronically infected patients without ATL

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old or older
* HTLV-1 infected
* T lymphoproliferation induced by HTLV-1 (cohort 1)
* without T lymphoproliferation induced by HTLV-1 (cohort 2)
* informed and accepted the collection of data

Exclusion Criteria

\- Patients refusal of participation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

URC-CIC Paris Descartes Necker Cochin

OTHER

Sponsor Role collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ambroise MARCAIS, MD

Role: PRINCIPAL_INVESTIGATOR

Assistance Publique-Hôpitaux Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Necker Enfants Malades

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ambroise MARCAIS, MD

Role: CONTACT

+33 1 44 49 46 99

Jinmi BAEK, Master

Role: CONTACT

+33 1 42 19 28 49

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ambroise MARCAIS, MD

Role: primary

01 44 49 46 99

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-A02320-39

Identifier Type: OTHER

Identifier Source: secondary_id

APHP180684

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.